Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 May;15(5):662–665. doi: 10.1128/aac.15.5.662

Treatment of Recurrent Herpes Simplex Labialis with Levamisole

S L Spruance 1, G G Krueger 2, J MacCalman 1, J C Overall Jr 3, M R Klauber †
PMCID: PMC352734  PMID: 525982

Abstract

Because deficient immune responses may play a contributory role in recurrent herpes simplex labialis, an immunomodulating agent, levamisole, has been advocated for therapy. Forty-two patients with a high frequency of recurrent herpes simplex labialis were followed for a mean of 7.8 months (range 4 to 12) and treated for 3 days at the onset of each episode of herpes with one of three different doses of levamisole or placebo in a randomized, double-blind study. Statistical analysis revealed that as the dosage increased, so did the frequency of recurrences (P = 0.007). Conversely, duration of the lesions and lesion pain decreased with increasing dosage (P = 0.05 and 0.03). These results indicate that levamisole is not an appropriate drug for the management of recurrent herpes simplex labialis. The paradoxical response to an immunomodulator (increased frequency, decreased severity) provides evidence that altered host responses may contribute to the pathogenesis of the disease.

Full text

PDF
662

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Grout P., Barber V. E. Cold sores-an epidemiological survey. J R Coll Gen Pract. 1976 Jun;26(167):428–434. [PMC free article] [PubMed] [Google Scholar]
  2. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. J Infect Dis. 1973 Sep;128(3):290–299. doi: 10.1093/infdis/128.3.290. [DOI] [PubMed] [Google Scholar]
  3. Kint A., Coucke C., Verlinden L. The treatment of recurrent herpes infections with levamisole. Arch Belg Dermatol. 1974 Jul-Sep;30(3):167–171. [PubMed] [Google Scholar]
  4. Mehr K. A., Albano L. Failure of levamisole in herpes simplex. Lancet. 1977 Oct 8;2(8041):773–774. doi: 10.1016/s0140-6736(77)90293-8. [DOI] [PubMed] [Google Scholar]
  5. Muller S. A., Herrmann E. C., Jr, Winkelmann R. K. Herpes simplex infections in hematologic malignancies. Am J Med. 1972 Jan;52(1):102–114. doi: 10.1016/0002-9343(72)90012-5. [DOI] [PubMed] [Google Scholar]
  6. Rand K. H., Rasmussen L. E., Pollard R. B., Arvin A., Merigan T. C. Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med. 1977 Jun 16;296(24):1372–1377. doi: 10.1056/NEJM197706162962402. [DOI] [PubMed] [Google Scholar]
  7. Russell A. S., Brisson E., Grace M. A double-blind, controlled trial of levamisole in the treatment of recurrent herpes labialis. J Infect Dis. 1978 May;137(5):597–600. doi: 10.1093/infdis/137.5.597. [DOI] [PubMed] [Google Scholar]
  8. Spruance S. L., Overall J. C., Jr, Kern E. R., Krueger G. G., Pliam V., Miller W. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med. 1977 Jul 14;297(2):69–75. doi: 10.1056/NEJM197707142970201. [DOI] [PubMed] [Google Scholar]
  9. Symoens J., Brugmans J. Letter: Treatment of recurrent aphthous stomatitis and herpes with levamisole. Br Med J. 1974 Dec 7;4(5944):592–592. doi: 10.1136/bmj.4.5944.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Symoens J., Rosenthal M. Levamisole in the modulation of the immune response: the current experimental and clinical state. J Reticuloendothel Soc. 1977 Mar;21(3):175–221. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES